General Information of Drug (ID: DMB24H7)

Drug Name
Motavizumab Drug Info
Synonyms MEDI-524; Motavizumab (USAN/INN)
Indication
Disease Entry ICD 11 Status REF
Respiratory syncytial virus infection 1C80 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMB24H7

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lasofoxifene DMHA18P Osteoporosis FB83.0 Approved [3]
Palivizumab DMQM9S0 Respiratory syncytial virus infection 1C80 Approved [4]
SAR438584 DMDMAE4 Respiratory syncytial virus infection 1C80 Phase 3 [5]
MK-1654 DM2YNMI Respiratory syncytial virus infection 1C80 Phase 2/3 [6]
GS-5806 DMDAHL6 Respiratory syncytial virus infection 1C80 Phase 2 [7]
RV521 DMSW5XJ Respiratory syncytial virus infection 1C80 Phase 2 [8]
JNJ-53718678 DMJ1FXL Respiratory syncytial virus infection 1C80 Phase 2 [9]
MEDI-557 DM6ADMG Respiratory syncytial virus infection 1C80 Phase 1 [2]
TMC-353121 DMDSJO8 Respiratory syncytial virus infection 1C80 Preclinical [3]
CL-387626 DMA4DNX Virus infection 1A24-1D9Z Terminated [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Respiratory syncytial virus protein F (RSV F) TT57ID8 FUS_HRSVA Modulator [2]

References

1 ClinicalTrials.gov (NCT00129766) Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children. U.S. National Institutes of Health.
2 Motavizumab. Correction in: MAbs. 2010 Sep-Oct; 2(5): 591.
3 Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr Opin Drug Discov Devel. 2009 Jul;12(4):479-87.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040470)
6 A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. Nat Commun. 2019 Sep 12;10(1):4153.
7 Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015 Feb 26;58(4):1630-43.
8 Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. J Med Chem. 2021 Apr 8;64(7):3658-3676.
9 Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study. J Infect Dis. 2018 Jul 24;218(5):748-756.
10 Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein. Viruses. 2013 January; 5(1): 211-225.